Alembic Pharma gets USFDA nod for Dapsone Gel 5%

Alembic Pharma gets USFDA nod for Dapsone Gel 5% Alembic Pharmaceuticals has received USFDA approval for Dapsone Gel 5%, a topical treatment for acne. The product will be marketed in the US market, expanding its dermatology portfolio. This approval positions APLLTD to tap into the growing demand for acne therapeutics. The US launch will be under its subsidiary, Alembic Pharmaceuticals Inc.

📊 STOCKS: APLLTD | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA